SOURCE: Biotie Therapies Oyj

May 16, 2008 05:06 ET

Biotie to present at The Rodman & Renshaw 5th Annual Global Healthcare Conference

TURKU, FINLAND--(Marketwire - May 16, 2008) -


BIOTIE THERAPIES CORP. Press Release May 16, 2008

Biotie to present at The Rodman & Renshaw 5th Annual Global Healthcare Conference

Live webcast will be available at www.biotie.com

Biotie Therapies Corp. (OMX: BTH1V) announced today that Dr. Timo Veromaa, President and Chief Executive Officer, will give an update on the company at the Rodman & Renshaw 5th Annual Global Healthcare Conference in Monaco on Tuesday, May 20, 2008 at 2:40 p.m. local time (3:40 p.m. Finnish time).

For more information on the conference: http://www.rodmanandrenshaw.com/conferences?id=18

The audio and slide presentation will be webcasted live and will be available for 90 days at www.biotie.com.

For further information:

Biotie Therapies Corp.
Timo Veromaa, President and CEO
Tel: +358 2 274 8901
timo.veromaa@biotie.com
www.biotie.com


Biotie Therapies Corp.

Biotie is a drug development company focusing on dependence disorders, inflammatory diseases and thrombosis. The most advanced programs are nalmefene for dependence disorders (phase III in alcoholism) and VAP-1 fully human monoclonal antibody for the treatment of inflammatory diseases (phase I). The nalmefene program is partnered worldwide, with Lundbeck as a key partner (license agreement with EUR 82 million milestone package plus royalties). Roche is a key partner in the inflammation programs with an option for the VAP-1 antibody program for a EUR 5 million option fee.

Biotie's shares are quoted on the OMX Nordic Exchange, Helsinki (Small cap, Healthcare).

For more information, please refer to www.biotie.com

Copyright © Hugin AS 2008. All rights reserved.

Contact Information